Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Orion Group Holdings Inc ORN

Orion Group Holdings, Inc. is a specialty construction company that serves the infrastructure, industrial, and building sectors. The Company provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin. It operates through two segments: marine and concrete. The marine segment provides construction and dredging services relating to... see more

NYSE:ORN - Post Discussion

Orion Group Holdings Inc > ORYZON receives minutes from End-of-Phase II meeting with th
View:
Post by whytestocks on Oct 01, 2024 2:45pm

ORYZON receives minutes from End-of-Phase II meeting with th

Just In: $ORN ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality DisorderFDA’s feedback supports the initiation of the Phase III trial Agitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indication Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2 Currently ...ORN - ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities